TNDM
HealthcareTandem Diabetes Care, Inc.
$23.15
+$1.60 (+7.42%)
Jan 5, 2026
Price History (1Y)
Analysis
Tandem Diabetes Care, Inc. is a healthcare company in the medical devices industry with a significant scale, boasting a market capitalization of $1.57 billion and revenue of $1.01 billion over the trailing 12 months (TTM). The company employs approximately 2,650 people. From a financial health perspective, Tandem Diabetes Care has faced challenges in terms of profitability, with gross margin sitting at 53.2%, but operating and profit margins registering losses of -8.0% and -20.2%, respectively. Returns on equity and assets are also negative, standing at -109.7% and -5.9%, respectively. The company's balance sheet is characterized by a debt-to-equity ratio of 341.58 and $319.11 million in cash on hand against $454.18 million in debt. Valuation metrics paint a mixed picture, with the forward price-to-earnings (P/E) ratio standing at -23.79. The company's revenue has grown by 2.2% year-over-year (YoY), although earnings growth is not available. The price-to-book ratio and price-to-sales ratios are 11.80 and 1.56, respectively.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $1.57B
- P/E Ratio
- N/A
- 52-Week High
- $38.18
- 52-Week Low
- $9.98
- Avg Volume
- 2.00M
- Beta
- 1.69
Company Info
- Industry
- Medical Devices
- Exchange
- NGM
- Country
- United States
- Employees
- 2,650